Sisu Pharma, a biotech company exploiting cellular stress to treat therapy-resistant cancers, is delighted to announce that Professor Michael Jung has joined its Scientific Advisory Board.
Breakthrough Study Shows Potential New Treatment for Therapy-Resistant Prostate Cancer
A new study published in the journal Science Translational Medicine has revealed a potential breakthrough in the treatment of therapy-resistant prostate cancer.
